Agendia Introduces New Breast Cancer Diagnostic Test
Posted on: Friday, 5 September 2008, 06:00 CDT
Agendia, a molecular cancer diagnostics company, has launched TargetPrint, a new diagnostic test that allows physicians to quantitatively determine the gene expression levels of the estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in breast cancer tumor biopsies.
According to the company, the accurate measurement of these receptors is of paramount importance in planning treatment of breast cancer patients after surgery and assists physicians and patients in making informed treatment decisions. TargetPrint runs on Agendia's new high density chip, which has earlier received market clearance from the FDA.
Bernhard Sixt, president and CEO of Agendia, said: "Currently available targeted therapies, such as hormone treatments, can have a huge impact on the survival and quality of life of a significant number of breast cancer patients. TargetPrint will play a key role in defining which patients are most likely to benefit from these treatments."
Source: Datamonitor
Related Articles
- Early-Stage, HER2-Positive Breast Cancer Patients At Increased Risk Of Recurrence
- FDA Grants IND for Pro-Pharmaceuticals' DAVANAT(R) to Treat Breast Cancer Patient
- N.L. Health Board Missed Dozens of Breast Cancer Patients
- Landmark Symposium Tackles Question of Why Breast Cancer Patients Don't Adhere to Hormone Therapy Regimes
- Important News for Breast Cancer Patients During National Breast Cancer Awareness Month
- New Drug Offers Hope to Breast Cancer Patients of Beating Illness
- 'Real Life' Study Clarifies Risk of Recurrence for High-Risk Breast Cancer Patients
- Study of Breast Cancer Patients Showed Regimen Including EMEND-R- -Aprepitant- Prevented Nausea and Vomiting After Chemotherapy in More Patients Than a Standard Regimen
- Breast Cancer Patients Boost Quality of Life While Taking Arimidex and Tamoxifen With Replens(TM) Vaginal Moisturizer
- Breast Cancer Patients Not Heeding Exercise Advice
 |
 |
User Comments (0)
RSS Feeds